Accessibility settings

Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/96402, first published .
Diagram of eye with labels for axial length, keratometry, CCT, and fundus changes in high myopia study.

Ocular Biometric and Fundus Characteristics in High Myopia: Protocol for a Hospital-Based Cross-Sectional Study

Ocular Biometric and Fundus Characteristics in High Myopia: Protocol for a Hospital-Based Cross-Sectional Study

Authors of this article:

Anshool Kumbhare1 Author Orcid Image ;   Pranaykumar Shinde1

Department of Ophthalmology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, Wardha, Maharashtra, India

*all authors contributed equally

Corresponding Author:

Anshool Kumbhare, MBBS


Background: High myopia (spherical equivalent refractive error [SER] ≤–6.00 diopters) is a prominent global cause of visual impairment, but its structural alterations are inadequately documented at all severity levels in Indian tertiary hospitals.

Objective: The aim of this study is to evaluate ocular biometric and fundus traits in high myopia and their relationship to the severity of myopia. The primary outcome is axial length measured using contact A-scan biometry. Meta-Analysis for Pathologic Myopia (META-PM) identified fundus changes, keratometry, central corneal thickness, and refractive astigmatism as secondary outcomes.

Methods: This hospital-based cross-sectional observational study at Acharya Vinoba Bhave Rural Hospital, India, will enroll 160 participants aged 10 to 50 years with high myopia (SER ≤−6.00 diopters in ≥1 eye) consecutively over 2 years. Ophthalmic examination will include best-corrected visual acuity (converted to logarithm of the minimum angle of resolution [logMAR]), cycloplegic refraction, slit-lamp biomicroscopy, keratometry, pachymetry, A-scan biometry, and dilated fundus examination (META-PM). Statistical analysis will involve the Shapiro-Wilk test, Pearson/Spearman correlation, ANOVA/Kruskal-Wallis, chi-square, and generalized estimating equations using SPSS (version 23; IBM Corp).

Results: The study received ethics approval on July 9, 2025. Enrollment has been ongoing since January 2026. Results are expected to be published in 2027 or 2028.

Conclusions: This study will provide region-specific data and guide evidence-based high myopia management.

Trial Registration: Clinical Trials Registry – India CTRI/2025/12/099253; https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTQzMTg1&Enc=&userName=099253

International Registered Report Identifier (IRRID): DERR1-10.2196/96402

JMIR Res Protoc 2026;15:e96402

doi:10.2196/96402

Keywords



Background

Myopia is a common vision problem worldwide (defined as spherical equivalent refractive error (SER) ≤−0.50 diopters [D]), but high myopia (SER ≤−6.00 D) is more serious [1]. It’s not just an optical inconvenience but a structural disease where progressive axial elongation raises the risk of vision-threatening concerns like myopic macular degeneration, glaucoma, retinal detachment, and cataracts [2,3]. Since risk increases exponentially with worsening myopia, distinguishing high myopia from low-to-moderate is clinically essential [1,3].

The prevalence of myopia has soared due to urbanization, intense schooling, and less outdoor time [4]. In Asia, up to 90% of school-aged children are myopic, and high myopia has a prevalence of up to 30% [5,6]. The prevalence of high myopia in 12-year-old children is 6.0%‐7.0% in Cambodia and New Delhi and 49.7%‐62% in China, Singapore, and Japan [7-10]. By 2050, approximately half of the world is anticipated to have myopia (10% high myopia), more than double compared to 2000 (and a fivefold increase for high myopia) [11].

High myopia diminishes quality of life beyond just blurry vision. The structural changes (elongation of the globe and progressive tissue thinning, corneal curvature alterations and fundus lesions like Fuchs spot, lacquer cracks, posterior staphyloma, and myopic crescent) are clinically recognized, yet how these changes vary across different levels of myopia severity remains poorly understood, particularly in cohorts from Central India [2,3,12].

Prior Work

Research has consistently shown that axial length is the key driver of myopia severity and is a strong predictor of structural complications [1,2]. Myopia control studies have used atropine, orthokeratology, progressive addition lenses, and defocus incorporated multiple segment lenses and have consistently used axial length as the primary end point [13-17], yet most studies focused on low-to-moderate myopia, leaving high myopia cohorts, particularly in South Asian tertiary care, largely uncharacterized [14].

Corneal parameters have also drawn attention in high myopia research. High myopia alters central corneal thickness (CCT) and corneal curvature, affecting refractive surgery candidacy and intraocular pressure measurement [3]. Astigmatism frequently coexists with high myopia, yet its precise distribution across myopia severity remains unclear in Indian cohorts.

Fundus changes are a critical concern in high myopia. The spectrum of funduscopic findings ranges from early signs (myopic crescent and tigroid fundus) to advanced lesions (posterior staphyloma, lacquer cracks, and choroidal neovascularization), each carrying distinct prognostic implications [2,12]. The Meta-Analysis for Pathologic Myopia (META-PM) classification standardizes grading of these lesions and is widely recommended [18]. A systematic META-PM–based evaluation of fundus changes across myopia severity levels therefore has considerable clinical value in a tertiary care hospital setting.

Study Objectives

The primary objective is to assess axial length in patients with high myopia and examine its relationship with the severity of myopia and associated pathological fundus changes. The secondary objectives are to assess myopic fundus changes using the META-PM classification; evaluate keratometry, CCT, and refractive astigmatism in relation to myopia severity; and determine the correlation between best-corrected visual acuity (BCVA) and axial length across myopia subgroups.

Outcome Measures

The primary outcome of the study will be axial length measured using contact A-scan ultrasound biometry and its association with the severity of high myopia.

Secondary outcomes will include the distribution and severity of myopic fundus changes graded using the META-PM classification, including lesions (lacquer cracks, posterior staphyloma, Fuchs spot, and peripheral retinal degeneration). Additional secondary outcomes will include CCT, keratometric parameters (K1 and K2), refractive astigmatism, and the association of BCVA with axial length and refractive severity.


Study Design and Setting

This will be a hospital-based, cross-sectional, observational study that will be conducted at Acharya Vinoba Bhave Rural Hospital, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research (Deemed to be University) (DMIHER [DU]), Maharashtra, India. The total duration of data collection is 2 years from the date of commencement (January 2026 to December 2027).

Sample Size

The sample size calculation followed the standard formula for estimating a single proportion:

n=Z² × p(1 − p) / d²

Where Z=1.96 at a 95% confidence interval, P=.10 based on prior studies reporting pathological fundus change prevalence in high myopia, and d=0.05 is the acceptable margin of error [2,3]. The calculated sample size was 139 and was rounded up to 160 to account for potential attrition and nonresponse.

Participant Selection

Patients presenting to the Department of Ophthalmology, Acharya Vinoba Bhave Rural Hospital, who fulfill the selection criteria, will be consecutively enrolled. The proposed screening, eligibility assessment, and recruitment process for participants is illustrated in Figure 1.

‎
Figure 1. Proposed participant flow diagram showing screening, eligibility assessment, recruitment, and inclusion of participants in the cross-sectional study evaluating ocular biometric parameters and fundus characteristics in high myopia.

Inclusion and Exclusion Criteria

Participants between 10 to 50 years of age with confirmed high myopia (defined as SER ≤−6.00 D in ≥1 eye on cycloplegic refraction) will be included. Both male and female participants willing to provide written informed consent (or written assent with parental/guardian consent for minors) will be enrolled. The upper age limit of 50 years was chosen to minimize confounding from age-related ocular changes including cataracts and age-related macular degeneration.

Patients with hypermetropia, active corneal lesions, significant lens opacities, active uveitis, previous intraocular or refractive surgery, or media opacities that preclude adequate fundus visualization will be excluded. Patients with systemic connective tissue disorders known to independently alter ocular biometric parameters (eg, Ehlers-Danlos syndrome, Marfan syndrome) will also be excluded. Individuals unwilling to participate or unable to comply with the examination protocol will not be enrolled.

Ethical Considerations

Ethics approval was obtained from the institutional ethics committee of DMIHER (DU) (reference number DMIHER(DU)/IEC/2025/393, dated July 9, 2025). The study was prospectively registered with the Clinical Trials Registry – India (CTRI/2025/12/099253) on December 16, 2025. The study will adhere to the Declaration of Helsinki and the Indian Council of Medical Research National Ethical Guidelines (2017).

Written informed consent will be obtained from all participants prior to enrollment, with legal guardians providing consent for participants <18 years of age. Consent forms are available in English, Hindi, and Marathi (Multimedia Appendices 1 and 2). Participant confidentiality will be maintained; all data will be anonymized before analysis and publication. Participation will be voluntary, and withdrawal will not affect the standard clinical care.

Data Collection

The principal investigator will perform all standardized ophthalmic evaluations and measurements to minimize interobserver variability. All instruments will be calibrated per manufacturer specifications (prior and during the study). Biometric measurements (axial length, CCT, and keratometry) will be averaged from 3 readings per eye. Pupillary dilation will use tropicamide 1% with or without phenylephrine 2.5%. Table 1 summarizes study variables and instruments. The assessments will be carried out for both eyes. A standardized proforma will be used to record all demographic, anthropometric, clinical, and biometric data (Multimedia Appendix 3).

Table 1. Study variables and measurement methods.
VariableMeasurement methodInstrument
Distance visual acuitySnellen chartSnellen chart at 6 m
Refractive error (SER)Cycloplegic retinoscopy and subjective refractionRetinoscope; autorefractometer
Axial lengthContact A-scan ultrasound biometryA-scan biometer
Central corneal thicknessContact ultrasound pachymetryUltrasound pachymeter
Corneal curvature (K1, K2)Automated keratometryAutokeratorefractometer
AstigmatismCycloplegic refractionRetinoscope; autorefractometer
Anterior segmentSlit-lamp biomicroscopySlit lamp
Fundus (META-PM grading)Dilated fundus examinationDirect and indirect ophthalmoscope

Demographic and Anthropometric Data

Each participant’s age, sex, occupation, educational level, weight, height, and BMI will be noted.

Visual Acuity

A Snellen chart will be used to measure BCVA for distance. Pinhole visual acuity will be recorded where needed. Snellen visual acuity will be rescaled to logarithm of the minimum angle of resolution (logMAR) units for statistical analysis.

Refraction

Retinoscopy will be used for objective refraction, followed by subjective refinement. In children and adolescents, cycloplegia will be induced using cyclopentolate 1% (two drops administered 5 minutes apart), and refraction will be carried out 30 minutes after the last drop. Postmydriatic assessment will be carried out the following day. Automated refraction will be recorded using an autorefractometer for cross-reference. The SER for each eye will be determined by combining the sphere with half the cylindrical power.

Slit-Lamp Biomicroscopy

Anterior segment evaluation will be performed to assess the cornea, anterior chamber, lens, and anterior vitreous for any relevant pathology.

Fundus Examination

A posterior segment assessment will be performed using dilated direct and indirect ophthalmoscopy. Fundus findings will be documented and categorized according to the META-PM classification system, which grades pathologic myopia lesions into the following categories: no myopic retinopathy (Category 0), tessellated fundus only (Category 1), diffuse chorioretinal atrophy (Category 2), patchy chorioretinal atrophy (Category 3), and macular atrophy (Category 4) [18]. Additional findings (myopic crescent, lacquer cracks, Fuchs spot, peripheral retinal degeneration, and posterior staphyloma) will also be recorded separately. Archived images will be independently reviewed by a second ophthalmologist for consistent META-PM grading.

Axial Length

Axial length will be measured using contact A-scan ultrasound biometry for each eye. Measurements will be analyzed across the following myopia severity subgroups based on SER: −6.00 D to −9.50 D, −10.00 D to −13.50 D, −14.00 D to −17.50 D, and ≤−18.00 D. These subgroup classifications were adapted from prior high-myopia stratification approaches used in pathological myopia and epidemiological studies [1,14,18].

Corneal Pachymetry

CCT will be measured using a contact ultrasound pachymeter. Measurements will be classified as: ≤480 micrometers (very thin), 481 to 500 micrometers (thin), 501 to 520 micrometers (borderline), 521 to 540 micrometers (normal), 541 to 560 micrometers (above average), and >560 micrometers (thick).

Keratometry

Corneal curvature (K1 and K2 readings) will be measured using automated keratometry. Mean keratometry values will be reported and correlated with the degree of myopia across the defined refractive subgroups.

Astigmatism

Total refractive astigmatism will be recorded and classified as 0 D, ≤1.00 D, 1.00 to 2.00 D, and >2.00 D, and analyzed across each myopia severity subgroup.

Bias and Missing Data Handling

Incomplete observations will be handled using complete-case analysis.

Data Management and Statistical Analysis

All data will be entered and maintained in a Microsoft Excel (version 2018; Microsoft Corp) spreadsheet. Statistical analysis will be performed using SPSS (version 23; IBM Corp). Descriptive statistics (means, standard deviations, frequencies, and percentages) will be used to summarize demographic and clinical characteristics. Data normality will be assessed using the Shapiro-Wilk test. Pearson or Spearman correlation coefficients will be used to assess relationships between continuous variables (axial length SER and BCVA). Comparison of ocular parameters across myopia severity subgroups will be performed using a 1-way ANOVA for normally distributed data or the Kruskal-Wallis test for nonparametric data. Categorical variables, including fundus findings, will be analyzed using the chi-square test or Fisher exact test where expected cell counts are small. Generalized estimating equations will be applied to account for intereye correlation when both eyes are included in the analysis. Multivariable linear regression analysis will be performed after adjusting for potential confounders including age, sex, and BMI. A P value <.05 will be considered statistically significant for all analyses.


As of the submission of this protocol manuscript, the study has received full ethical clearance. Participant enrollment commenced in January 2026 and is currently ongoing. The target sample size is 160 participants. Results are expected to be available for analysis and publication by 2027 to 2028. The anticipated study timeline is presented in Table 2.

Table 2. Anticipated study timeline.
PhaseActivityPeriod
Phase 1Ethics approval and Clinical Trials Registry – India registrationCompleted (July to December 2025)
Phase 2Participant recruitment and data collectionJanuary 2026 to December 2027
Phase 3Data cleaning and statistical analysisJanuary 2028 to March 2028
Phase 4Manuscript preparation and submissionApril 2028 to June 2028

Principal Findings (Anticipated)

This study protocol is designed to document the distribution of axial length, CCT, keratometry, astigmatism, and META-PM–graded fundus pathology across the graded spectrum of high myopia in a tertiary care cohort in Central India. We anticipate a strong positive correlation between axial length and myopia severity, with increasing frequency and severity of pathological fundus findings in higher myopia subgroups. Variation in CCT and keratometric values across subgroups will have direct implications for refractive surgery planning.

Comparison With Prior Work

Prior reviews have consistently identified axial length as the key biomarker of myopia progression [13-17]. A recent review noted the scarcity of dedicated high-myopia data despite disproportionate complications risk [14]. Our study addresses this gap by focusing solely on high myopia and recording extensive structural and biometric parameters.

While most prior research with large sample sizes has been conducted in East Asian populations, limited data exist that specifically characterize the comprehensive panel of ocular parameters, including axial length, corneal findings, and fundus changes, in a high myopia cohort from Central India [5,6,9,10]. Differences in ethnic background, behavioral patterns, and environmental exposures may produce findings that diverge from East Asian cohorts, and our study is positioned to contribute these region-specific data [19,20].

Clinical Implications

The anticipated findings of this study may improve risk stratification and clinical monitoring strategies in highly myopic patients attending tertiary care centers. Identification of ocular biometric markers associated with pathological fundus changes may support earlier surveillance and intervention in patients at higher risk of visual morbidity. The findings may also assist clinicians in refractive surgery evaluation and long-term management planning in highly myopic populations.

Strengths and Limitations

This study has several notable strengths. This will be the first prospectively registered, ethics-approved cross-sectional study in Central India to document a comprehensive panel of ocular biometric and structural parameters (axial length, CCT, keratometry, astigmatism, and META-PM–graded fundus findings) specifically in a high myopia cohort. The validated META-PM classification system will ensure reproducibility and comparability, while generalized estimating equations will account for intereye correlation, strengthening analytical rigor.

Several limitations are acknowledged. The cross-sectional design will preclude causality and temporal progression of ocular changes. Hospital-based recruitment may introduce selection bias, as a tertiary referral center may see more severe disease than the community populations. The absence of an emmetropic control group will limit direct comparison with normative parameters. Single center conduct may affect generalizability across India’s diverse population. Additionally, contact ultrasound biometry may have greater measurement variability than optical biometry. These limitations will be discussed in detail in the final publication of results.

Future Directions

Future longitudinal studies using optical biometry and multimodal retinal imaging may clarify temporal progression of structural ocular changes in high myopia. Future multicenter studies with larger, diverse populations may improve generalizability and enable region-specific screening for pathological myopia.

Dissemination Plan

Study findings will be disseminated through peer-reviewed journal publications, conference presentations, and institutional academic forums. Deidentified aggregate data may contribute to future regional epidemiological research on high myopia and pathological myopia.

Conclusions

This protocol presents a comprehensive, ethics-approved, and prospectively registered cross-sectional study evaluating ocular parameters in patients with high myopia at a tertiary care hospital in Central India. The study is designed to generate clinically relevant data on fundus changes, axial length, keratometry, CCT, and astigmatism across the spectrum of high myopia. Findings from this study are expected to inform evidence-based approaches to the monitoring and management of high myopia in the Indian population and contribute to the growing global body of literature on this significant public health issue.

Acknowledgments

No generative AI or AI-assisted technologies were used in the generation of scientific content, study design, data interpretation, or final conclusions of this manuscript. The authors acknowledge the use of Grammarly and Quillbot solely for language refinement and grammar checking. All scientific content, intellectual contributions, and final manuscript revisions are the original work of the authors.

Funding

This study is self-funded by the investigators. No external grant funding has been received. All authors declared that they had insufficient funding to support open access publication of this manuscript, including from affiliated organizations or institutions, funding agencies, or other organizations. JMIR Publications provided article processing fee (APF) support for the publication of this article.

Data Availability

Deidentified data underlying the findings of this study will be available from the corresponding author upon reasonable request following publication, in accordance with institutional data governance policies and the Indian Council of Medical Research National Ethical Guidelines (2017). Study data will be stored securely for a minimum of 5 years after publication.

Authors' Contributions

Conceptualization: AK

Data curation: AK

Formal analysis: AK

Investigation: AK

Methodology: AK

Writing – original draft: AK

Supervision: PS

Validation: PS

Writing – review and editing: PS

Conflicts of Interest

None declared.

Multimedia Appendix 1

Patient information sheet.

DOCX File, 25 KB

Multimedia Appendix 2

Patient consent form.

DOCX File, 21 KB

Multimedia Appendix 3

Proforma for data collection.

DOCX File, 21 KB

  1. Flitcroft DI, He M, Jonas JB, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. Feb 28, 2019;60(3):M20-M30. [CrossRef] [Medline]
  2. Cho BJ, Shin JY, Yu HG. Complications of pathologic myopia. Eye Contact Lens. Jan 2016;42(1):9-15. [CrossRef] [Medline]
  3. Ikuno Y. Overview of the complications of high myopia. Retina. Dec 2017;37(12):2347-2351. [CrossRef] [Medline]
  4. Morgan IG, Wu PC, Ostrin LA, et al. IMI risk factors for myopia. Invest Ophthalmol Vis Sci. Apr 28, 2021;62(5):3. [CrossRef] [Medline]
  5. Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta‐analysis and systematic review. Acta Ophthalmol (Copenh). Sep 2017;95(6):551-566. [CrossRef]
  6. Tariq F, Mobeen R, Wang X, et al. Advances in myopia prevention strategies for school-aged children: a comprehensive review. Front Public Health. 2023;11:1226438. [CrossRef] [Medline]
  7. Ip JM, Huynh SC, Robaei D, et al. Ethnic differences in refraction and ocular biometry in a population-based sample of 11-15-year-old Australian children. Eye (Lond). May 2008;22(5):649-656. [CrossRef] [Medline]
  8. Murthy GVS, Gupta SK, Ellwein LB, et al. Refractive error in children in an urban population in New Delhi. Invest Ophthalmol Vis Sci. Mar 2002;43(3):623-631. [Medline]
  9. Saw SM, Tong L, Chua WH, et al. Incidence and progression of myopia in Singaporean school children. Invest Ophthalmol Vis Sci. Jan 2005;46(1):51-57. [CrossRef] [Medline]
  10. Ramamurthy D, Lin Chua SY, Saw SM. A review of environmental risk factors for myopia during early life, childhood and adolescence. Clin Exp Optom. Nov 2015;98(6):497-506. [CrossRef] [Medline]
  11. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. May 2016;123(5):1036-1042. [CrossRef] [Medline]
  12. Wolffsohn JS, Jong M, Smith EL 3rd, et al. IMI 2021 reports and digest - reflections on the implications for clinical practice. Invest Ophthalmol Vis Sci. Apr 28, 2021;62(5):1. [CrossRef] [Medline]
  13. Eppenberger LS, Grzybowski A, Schmetterer L, Ang M. Myopia control: are we ready for an evidence based approach? Ophthalmol Ther. Jun 2024;13(6):1453-1477. [CrossRef] [Medline]
  14. Shah R, Vlasak N, Evans BJW. High myopia: reviews of myopia control strategies and myopia complications. Ophthalmic Physiol Opt. Sep 2024;44(6):1248-1260. [CrossRef] [Medline]
  15. Li Y, Fu Y, Wang K, Liu Z, Shi X, Zhao M. Evaluating the myopia progression control efficacy of defocus incorporated multiple segments (DIMS) lenses and Apollo progressive addition spectacle lenses (PALs) in 6- to 12-year-old children: study protocol for a prospective, multicenter, randomized controlled trial. Trials. Mar 19, 2020;21(1):279. [CrossRef] [Medline]
  16. Wang F, Wu G, Xu X, et al. Orthokeratology combined with spectacles in moderate to high myopia adolescents. Cont Lens Anterior Eye. Feb 2024;47(1):102088. [CrossRef] [Medline]
  17. Walline JJ, Lindsley KB, Vedula SS, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. Jan 13, 2020;1(1):CD004916. [CrossRef] [Medline]
  18. Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. May 2015;159(5):877-883. [CrossRef] [Medline]
  19. He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia among children in china: a randomized clinical trial. JAMA. Sep 15, 2015;314(11):1142-1148. [CrossRef] [Medline]
  20. Armarnik S, Lavid M, Blum S, Wygnanski-Jaffe T, Granet DB, Kinori M. The relationship between education levels, lifestyle, and religion regarding the prevalence of myopia in Israel. BMC Ophthalmol. Mar 16, 2021;21(1):136. [CrossRef] [Medline]


‎
BCVA: best-corrected visual acuity
CCT: central corneal thickness
D: diopters
DMIHER (DU): Datta Meghe Institute of Higher Education and Research (Deemed to be University)
logMAR: logarithm of the minimum angle of resolution
META-PM: Meta-Analysis for Pathologic Myopia
SER: spherical equivalent refractive error


Edited by Javad Sarvestan; submitted 28.Mar.2026; peer-reviewed by Abraham Garcia-Gil, Lucky Ilodigwe; final revised version received 16.May.2026; accepted 28.May.2026; published 03.Nov.2026.

Copyright

© Anshool Kumbhare, Pranaykumar Shinde. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 3.Nov.2026.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.